Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | EHMT2 | Q96KQ7 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | TDO2 | P48775 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.38 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | NSD2 | O96028 | 1/20 | 0.36 |
| ▸ | UBE2M | P61081 | 1/20 | 0.36 |
| ▸ | DCUN1D1 | Q96GG9 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12074539 | 0.82 | POLB (0.44) | EHMT2ALDH1A1 | |
| SCHEMBL12988831 | 0.81 | KDM4E (0.53) | KDM4EL3MBTL1RECQLMEN1KMT2A | |
| SCHEMBL12990035 | 0.80 | IL1B (0.40) | KDM4EMEN1KMT2AGRIN2B | |
| SCHEMBL12074551 | 0.75 | RAPGEF4 (0.45) | EHMT2 | |
| SCHEMBL13756997 | 0.73 | NOS2 (0.41) | EHMT2MEN1KMT2AALDH1A1 | |
| SCHEMBL12989911 | 0.73 | POLB (0.45) | EHMT2ALDH1A1JAK1 | |
| SCHEMBL13757011 | 0.72 | KDM4E (0.57) | KDM4EL3MBTL1RECQLMEN1KMT2A | |
| SCHEMBL13757024 | 0.71 | TP53 (0.38) | KDM4EL3MBTL1ALDH1A1GAAUBE2M | |
| SCHEMBL15305191 | 0.70 | POLB (0.45) | KDM4EEHMT2MEN1KMT2AALDH1A1 | |
| SCHEMBL15787991 | 0.69 | DRD4 (0.47) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404674-B2 | Substituted 9H-purin-2-YL compounds, compositions thereof and uses thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-03-26 | — | — | US | disclosed |
| US-20100311721-A1 | COMPOUNDS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-12-09 | — | — | US | disclosed |
| US-7569561-B2 | 2,4-diaminopyrimidines useful for treating cell proliferation diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-08-04 | — | — | US | disclosed |
| US-20070207999-A1 | New Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100311721-A1 | COMPOUNDS | CCNA1, MKI67, CCNT1 | KDM4E 2796/4885L3MBTL1 1207/4885RECQL 1628/4885 |
| US-20070207999-A1 | New Compounds | CCNA1, MKI67, CCNT1 | KDM4E 3005/4885L3MBTL1 1771/4885RECQL 901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.